Navigation Links
GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
Date:11/10/2008

ATLANTA, Nov. 10 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) ("GeoVax" or "the Company"), a biopharmaceutical firm developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2008 financial results and provided an operational update.

Robert McNally, GeoVax's President and CEO, commented, "We are very pleased with the progress we've made during the third quarter of 2008 and for the year so far, as we've taken steps to address both short-term and long-term goals. We made a shipment of the vaccine to the HIV Vaccine Trials Network during October, which is a significant step in preparation for the largest clinical trial yet to be undertaken by GeoVax and we look forward to HVTN's initiation of the Phase 2a trial later this year. We are also nearing completion of a license with Vivalis S.A., a French biopharmaceutical company, for manufacturing platform technology for the MVA portion of our vaccine that we anticipate will significantly improve the long-term production capabilities for the vaccine."

Financial Results for the Three Months and Nine Months Ended September 30, 2008

The Company recorded a net loss of $722,108 for the three months ended September 30, 2008, compared to $1,165,519 for the same period in 2007. For the nine months ended September 30, 2008, the Company's net loss was $2,688,970 as compared to $3,085,926 in 2007. Net losses for 2008 were partially offset by grant revenues of $1,322,502 and $2,298,571 for the three month and nine month periods, respectively, related to the Company's grant from the National Institutes of Health (NIH) in support of its HIV/AIDS vaccine development activities. As of September 30, 2008, the Company reported cash balances totaling $2,784,706.

Summarized financial information is attached. Further information concerning the Company's financial position and results of operation
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a ... check the legal requirements around using controlled substances in ... , As their international operations expand and become increasingly ... built as a result of the first phase of ...
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, ... Sequenom, Inc. (NASDAQ: SQNM ), the ... agreement for next generation noninvasive prenatal tests (NIPT). ... interpretation technology, called Mantis™, to advance analysis of ...
(Date:12/25/2014)... The report “Service Quality Management and ... Provider Type - Global Advancements, Worldwide Forecasts & Analysis ... analysis and forecasting of revenues. , Browse 152 ... and in-depth TOC on “Service Quality Management (SQM) and ...
(Date:12/24/2014)... Solutions , Inc. (NASDAQ: BLFS ), a leading ... storage and cryopreservation freeze media and ... or the "Company"), today announced that it will hold its ... "Annual Meeting"). Because the expected date for the ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... Oct. 9 A homegrown New Jersey company ... pedigree of pharmaceuticals everywhere. Secure Symbology, (http://www.securesymbology.com ), ... as an,Honored Finalist as Emerging Business of the ... for its vision to wipe out counterfeit drugs,worldwide. ...
... Inc.,(Nasdaq: ORCH ), a leading worldwide provider ... of James F. Smith as Vice,President and Chief ... A. Bologna, Orchid Cellmark,s President and Chief Executive ... Orchid Cellmark more than 25 years of,extensive domestic ...
... 9 Tandem Labs, a leading contract,research ... (PD) services to the pharmaceutical,industry, announced that ... 5000(TM),and 4000(TM) LC/MS/MS systems for its New ... the facility,s current triple,quadrupole LC/MS/MS capacity, allowing ...
Cached Biology Technology:Secure Symbology: Making New Jersey Proud While Saving Lives 2Orchid Cellmark Appoints James F. Smith Chief Financial Officer 2Orchid Cellmark Appoints James F. Smith Chief Financial Officer 3Tandem Labs' New England Facility Doubles Discovery Support Capacity - Increasing Foothold in New England 2
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ...
(Date:12/15/2014)... 12, 2014 Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... Facial Recognition Market 2015-2019" report to their offering. ... Facial recognition is a technology used for the identification ... feature of a person such as nose, jaw edges, ...
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... international effort to assess the status of dozens of European ... northeast Atlantic are being fished sustainably today and that, given ... in the Cell Press journal Current Biology on ... that the European Union,s Common Fisheries Policy is failing, the ...
... the time, it takes decades of accumulating genetic errors for ... of cancer in adults, it leaves a gap in understanding ... published in the July issue of the Proceedings of ... piece of the pediatric cancer puzzle. Changxian Shen, PhD, senior ...
... (July 19, 2013) Researchers at the University of ... gene associated with human autoimmune disease. The ... set into motion new treatment approaches for autoimmune diseases ... key to these advances may lie with a better ...
Cached Biology News:European fish stocks poised for recovery 2Study finds missing piece of pediatric cancer puzzle 2U of M researchers identify new functions for autoimmune disease 'risk' gene 2
...
... Drummond Scientific has a long ... of microinjection apparatus. Several years ago ... positive displacement microdispenser was being modified ... this unit by redesigning the microdispenser ...
The Programmable MP-3500P-F Power Supply can be applied for any Microfluidic application....
... Smart Minis 150V power supply (Cat. No. ... supplies designed to meet most electrophoresis needs ... unit. The Minis 150V power supply is ... Power Supply is designed for individuals to ...
Biology Products: